Medicinal Inorganic Chemistry Group, Department of Chemistry , University of British Columbia , 2036 Main Mall , Vancouver , British Columbia V6T 1Z1 , Canada.
Life Sciences Division , TRIUMF , 4004 Wesbrook Mall , Vancouver , British Columbia V6T 2A3 , Canada.
Inorg Chem. 2019 Jul 1;58(13):8685-8693. doi: 10.1021/acs.inorgchem.9b01016. Epub 2019 Jun 18.
In this study, we present the synthesis and characterization of the octadentate bispidine ligand, Hbispox and its complexes with medicinally useful radiometal nuclides (In and Lu), including their X-ray diffraction single crystal structures with the stable isotopes. InCl radiolabels the ligand quantitatively at ambient conditions ([L] = 10 M, room temperature, pH 7 and 15 min) and the in vitro human serum stability assays demonstrated high stability of the [In(bispox)] complex over 5 days. Moreover, the β emitter Lu radiolabels the ligand at 37 °C in 30 min (pH 8). These initial investigations reveal the potential of the octadentate bispidine ligand Hbispox as a useful chelator for In and Lu-based radiopharmaceuticals.
在这项研究中,我们提出了八齿双齿配体 Hbispox 的合成和表征,以及其与医学有用的放射性金属核素(In 和 Lu)的配合物,包括它们与稳定同位素的 X 射线衍射单晶结构。在环境条件下([L] = 10 M,室温,pH 7 和 15 分钟),InCl 定量标记配体,体外人血清稳定性试验表明[In(双齿配体)]配合物在 5 天内具有很高的稳定性。此外,β 发射器 Lu 在 37°C 下于 30 分钟内(pH 8)标记配体。这些初步研究揭示了八齿双齿配体 Hbispox 作为基于 In 和 Lu 的放射性药物的有用螯合剂的潜力。